EUVIMEDEUVIMED entdecken
Crossref

Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer

Yutaka Yamamoto, Naoki Matsumura, Saizou Fujimoto, Tsuyoshi Morita, Taizo Uchimoto, Wataru Fukuokaya, Masanobu Saruta, Seitetsu Sugiyama, Keita Tamura, Haruhito Azuma, Takahiro Kimura, Kiyoshi Takahara und 3 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yutaka Yamamoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Nara Hospital, Nara, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Oncological outcomes for metastatic castration-sensitive prostate cancer (mCSPC) have improved with upfront androgen receptor signaling inhibitor (ARSI) doublet therapy. However, the prognostic value of prostate-specific antigen (PSA) kinetics in real-world settings remains unclear. This study aimed to evaluate the clinical significance of PSA kinetics in patients with high-risk mCSPC. PATIENTS AND METHODS: We retrospectively analyzed 352 patients with high-risk mCSPC from the ULTRA-J database who received upfront ARSI doublet therapy between 2018 and 2023. PSA kinetics, including PSA nadir, PSA response rate, and time to PSA nadir (TTN), were assessed. Associations with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: A PSA nadir ≤0.02 ng/ml and PSA response rate ≥99% were significantly associated with prolonged CRPC-FS and OS (p 0.02 ng/ml, PSA response rate

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantHumansMaleRetrospective StudiesPrognosisAgedKineticsMiddle AgedAndrogen Receptor AntagonistsTreatment OutcomeAged, 80 and overNeoplasm MetastasisBiomarkers, Tumor

Stichwörter der Autor:innen

Metastatic castration-sensitive prostate cancerPSA kineticsandrogen receptor signaling inhibitor

Substanzen

Prostate-Specific AntigenAndrogen Receptor AntagonistsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Kindai University Nara Hospital, Nara, Japan.
  • Department of Urology, Kindai University Hospital, Osaka, Japan.
  • Department of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
  • Department of Urology, The Jikei University Hospital, Tokyo, Japan.
  • Department of Urology, Fujita Health University Hospital, Aichi, Japan.
  • Department of Urology, Kawasaki Medical School, Okayama, Japan.

Zitieren

APA

Yamamoto, Y., Matsumura, N., Fujimoto, S., Morita, T., Uchimoto, T., Fukuokaya, W., Saruta, M., Sugiyama, S., Tamura, K., Azuma, H., Kimura, T., Takahara, K., Komura, K., Inamoto, T., & Fujita, K. (2026). Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.18206

Vancouver

Yamamoto Y, Matsumura N, Fujimoto S, Morita T, Uchimoto T, Fukuokaya W, et al. Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer. Anticancer Research. 2026. doi:10.21873/anticanres.18206

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Yutaka and Matsumura, Naoki and Fujimoto, Saizou and Morita, Tsuyoshi and Uchimoto, Taizo and Fukuokaya, Wataru and Saruta, Masanobu and Sugiyama, Seitetsu and Tamura, Keita and Azuma, Haruhito and Kimura, Takahiro and Takahara, Kiyoshi and Komura, Kazumasa and Inamoto, Teruo and Fujita, Kazutoshi},
  title = {Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18206}
}
Kostenlos starten →